CA2743590A1 - Diagnosis of multiple sclerosis - Google Patents

Diagnosis of multiple sclerosis Download PDF

Info

Publication number
CA2743590A1
CA2743590A1 CA2743590A CA2743590A CA2743590A1 CA 2743590 A1 CA2743590 A1 CA 2743590A1 CA 2743590 A CA2743590 A CA 2743590A CA 2743590 A CA2743590 A CA 2743590A CA 2743590 A1 CA2743590 A1 CA 2743590A1
Authority
CA
Canada
Prior art keywords
antigens
pattern
listed
reactivity
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2743590A
Other languages
English (en)
French (fr)
Inventor
Howard L. Weiner
Irun R. Cohen
Francisco J. Quintana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Brigham and Womens Hospital Inc
Original Assignee
Yeda Research and Development Co Ltd
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Brigham and Womens Hospital Inc filed Critical Yeda Research and Development Co Ltd
Publication of CA2743590A1 publication Critical patent/CA2743590A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2743590A 2008-11-12 2009-11-12 Diagnosis of multiple sclerosis Abandoned CA2743590A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11364508P 2008-11-12 2008-11-12
US61/113,645 2008-11-12
PCT/IL2009/001066 WO2010055510A2 (en) 2008-11-12 2009-11-12 Diagnosis of multiple sclerosis

Publications (1)

Publication Number Publication Date
CA2743590A1 true CA2743590A1 (en) 2010-05-20

Family

ID=42170484

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2743590A Abandoned CA2743590A1 (en) 2008-11-12 2009-11-12 Diagnosis of multiple sclerosis

Country Status (7)

Country Link
US (1) US9267945B2 (enExample)
EP (1) EP2353004B1 (enExample)
JP (1) JP2012508865A (enExample)
CN (1) CN102388307B (enExample)
AU (1) AU2009315230A1 (enExample)
CA (1) CA2743590A1 (enExample)
WO (1) WO2010055510A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140105980A1 (en) 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP4265267A3 (en) 2010-10-19 2024-01-17 Op-T LLC Peptides for modulating t-cell activity and uses thereof
US20190263888A1 (en) 2010-10-19 2019-08-29 Op-T Llc Therapeutic peptides and methods for treating autoimmune related disease
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US8652999B1 (en) 2012-07-24 2014-02-18 Dow Agrosciences, Llc. Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and a sulfonylaminocarbonyltriazolinone
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
WO2015089443A2 (en) * 2013-12-12 2015-06-18 The Brigham And Women's Hospital, Inc. Treating neurodegenerative disease
US20160320384A1 (en) 2013-12-31 2016-11-03 Yeda Research And Development Co. Ltd. Methods for assaying immunological competence
EP3090064B1 (en) 2013-12-31 2019-11-13 Yeda Research and Development Co. Ltd. Diagnosis of systemic lupus erythematosus using oligonucleotides antigens
WO2015148389A2 (en) * 2014-03-23 2015-10-01 The Regents Of The University Of Colorado Diagnosis of multiple sclerosis in human and animal subjects
EP2927687A1 (en) * 2014-03-31 2015-10-07 Ecole Polytechnique Federale de Lausanne (EPFL) Agents useful in diagnostic and therapy of beta-amyloid aggregation related disorders and screening methods
WO2015172008A1 (en) * 2014-05-09 2015-11-12 Multiple Sclerosis Research Center Of New York Transglutaminadase 6 as a biomarker for multiple sclerosis
US10495646B2 (en) 2015-01-30 2019-12-03 The Regents Of The University Of California N-acetyl glucosamine as a biomarker of MS disease course
WO2016139659A1 (en) 2015-03-01 2016-09-09 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
US12011480B2 (en) 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN107043413A (zh) * 2016-02-05 2017-08-15 华中农业大学 一种肺结核相关的尿液生物标志蛋白及其应用
EP3509646A4 (en) * 2016-09-09 2020-06-17 Mayo Foundation for Medical Education and Research METHOD AND MATERIALS FOR IDENTIFYING AND TREATING AUTOIMMUNE GFAP ASTROCYTOPATHY
EP3538559B1 (en) 2016-11-09 2025-04-09 UTI Limited Partnership Recombinant pmhc class ii molecules
RU2019135533A (ru) 2017-04-07 2021-05-07 Ютиай Лимитед Партнершип Анализ измерения эффективности рецепторно-лигандных взаимодействий в лекарственных нанолекарственных средствах
CN111741746A (zh) 2017-11-29 2020-10-02 乌第有限合伙公司 治疗自身免疫性疾病的方法
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
US12048734B2 (en) 2020-04-17 2024-07-30 Op-T Llc Bioactive peptides and methods of use thereof
CN114689865A (zh) * 2020-12-30 2022-07-01 广州市微米生物科技有限公司 视神经脊髓炎抗体检测试剂
CN113336862B (zh) * 2021-07-05 2022-03-01 广东省科学院动物研究所 一种抗多发性硬化的重组蛋白及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
EP2236156A3 (en) * 2001-01-09 2011-01-05 Baylor Research Institute Methods for treating and diagnosing Psoriasis
EP2302387A1 (en) 2001-04-10 2011-03-30 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic uses of antibody specificity profiles for insulin-dependent diabetes mellitus
US20030092089A1 (en) 2001-11-14 2003-05-15 Moscarello Mario Anthony Method for diagnosing multiple sclerosis and an assay therefore
IL148401A0 (en) * 2002-02-26 2002-09-12 Hadasit Med Res Service Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases
EP1597557A4 (en) 2002-10-11 2008-06-11 Univ California PROCESS FOR THE DIAGNOSIS AND FORECAST OF MULTIPLE SCLEROSIS
US20050260770A1 (en) 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
BRPI0512921A (pt) 2004-07-01 2008-04-22 Den Kgl Veterinaer Og Landboho processo para tratamento e profilaxia de ms
WO2006077126A2 (en) 2005-01-19 2006-07-27 Bayer Schering Pharma Aktiengesellschaft Cx3cr1 as a marker which correlates with both disease and disease activity in multiple sclerosis patients
US7572592B2 (en) 2005-01-31 2009-08-11 Glycominds Ltd Method for diagnosing multiple sclerosis
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
WO2006116155A2 (en) * 2005-04-21 2006-11-02 The Regents Of The University Of California A method for diagnosis and prognosis of multiple sclerosis subtypes
WO2007014001A2 (en) * 2005-07-21 2007-02-01 The Board Of Trustees Of The Leland Stanford Junior University Multiplex determination of lipid specific binding moieties
WO2007056332A2 (en) 2005-11-07 2007-05-18 Vanderbilt University Molecular diagnosis of autoimmune diseases
EP3231789A1 (en) 2006-05-26 2017-10-18 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
EP2579038B1 (en) * 2007-04-12 2014-10-01 Universiteit Hasselt Biomarkers for multiple sclerosis

Also Published As

Publication number Publication date
EP2353004A2 (en) 2011-08-10
US9267945B2 (en) 2016-02-23
JP2012508865A (ja) 2012-04-12
AU2009315230A1 (en) 2010-05-20
US20120077686A1 (en) 2012-03-29
EP2353004A4 (en) 2012-04-18
CN102388307A (zh) 2012-03-21
HK1168423A1 (en) 2012-12-28
CN102388307B (zh) 2014-09-03
WO2010055510A2 (en) 2010-05-20
EP2353004B1 (en) 2018-01-03
WO2010055510A3 (en) 2010-09-16

Similar Documents

Publication Publication Date Title
US9267945B2 (en) Diagnosis of multiple sclerosis
US20250067754A1 (en) Methods and compositions for diagnosing brain injury or neurodegeneration
JP4659025B2 (ja) 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質
DK2558862T3 (en) DIAGNOSTIC PROCEDURES FOR GLAUCOMA
US20140370531A1 (en) Method of diagnosing mild traumatic brain injury
JPWO2018221212A1 (ja) アルツハイマー病バイオマーカー
JP2024019509A (ja) アルツハイマー病又は発症前アルツハイマー病の診断用マーカー及び診断用キット、脳内へのアミロイドβタンパク質の蓄積量の評価方法、並びに被験者におけるアルツハイマー病又は発症前アルツハイマー病の検出を補助するためのインビトロの方法
CN119895264A (zh) 检测标志物、诊断标志物及其用途、试剂盒
Virhammar et al. Biomarkers for CNS injury in CSF are elevated in COVID-19 and associated with neurological symptoms and disease severity
Zhang et al. Characteristics of recurrence in area postrema-onset NMO spectrum disorder-a retrospective cohort study
US11619632B2 (en) Early-stage Alzheimer's disease autoantibody biomarkers, target antigens and diagnostic uses thereof
Zhang et al. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus
Nakane et al. Ganglionic acetylcholine receptor autoantibodies in patients with Guillain-Barre syndrome
US10088486B2 (en) Method for detecting neurological disease accompanied by inflammation and/or demyelination
Gao et al. Neuropsychological features in patients with general paresis of the insane at an early stage
JP7280610B2 (ja) 細胞内コレステロールレベルに関連する疾患の、診断用マーカー、診断を補助する方法、診断のためにデータを収集する方法、罹患可能性を評価する方法、及び診断用キット
Jakobsson et al. Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease
HK1168423B (en) Diagnosis of multiple sclerosis
CN104704365A (zh) 精神分裂症标记物组及其利用
US20180120333A1 (en) Diagnostic markers of cognitive impairments, kits and uses thereof
JP2020153832A (ja) オートタキシン測定による神経障害性疼痛を検出する方法及び検出試薬
US20220236290A1 (en) Methods, systems and compositions for traumatic brain injury and associated neurodegenerative disease immune response diagnostics
Grgić et al. Prognostic significance of intrathecal oligoclonal immunoglobulin G in multiple sclerosis
Haven et al. Antibody Detection Methods for Neural Autoantibodies and Introduction to Antibody Pathogenesis
RU2531922C2 (ru) Способ молекулярной диагностики состояния психосоматических функций у пациентов с дисциркуляторной энцефалопатией

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141021

FZDE Discontinued

Effective date: 20191113